Description

Avant Imunotherapeutics is a BioTek working on several potentially large
new drugs.They have 3 products in advanced development, TP10 for both adult
and pediatric cardiac surgery indications,Rotarix with GlaxoSmithKline
for rotavirus disease (acute diarrhea)Peru15 with Walter Reade Army Research Institute Cholera and Typhoid fever vaccine.

Other promising products are Ceti 1 which raises good HDL levels for
chlosteral management.TP20 inhibitor for strokes.Therapore for Hepatitus
and Aids.They also own Megan Health which is licensed by Pfizer for use
in animal health and food safety vaccines including E coli infection.

Current collaborative agreements are with Novartis for up to $20 million
in milestone payments fot TP10. Aventis for $18.2 million for Adjumer
and Micromer formulated vaccaines for influenza,lyme disease and other
vaccines.Walter Reade (US Army) for chronic viral infections and cancer
using Therapore and the first target is HIV. Pfizer $5.5 million for animal
health and food vaccines.

If Avant is succesfull in developing just one of the above products
it's price will go to 20 -40 in 2-4 years. They are also a takeover
candiate due to their product pipeline and low price.

Catalyst

Avant's stock recently declined due to DSMB halting pediatric trials
of TP10. Advant supplied the DSMB with the requested data and the DSMB
allowed Advant to resume enrollment and to continue the trials. Advant
thinks the FDA may also want to review this data which may delay the
trials by 3 months which caused the stock to drop by 30%.This was only
for the pediatric trials and the adult trials continue on schedule.

The stock could jump sharply as there are rumors (Business Week) of a
potental investment by a major Drug company.Other knowledgeable drug
analysts see major takeovers of low priced BioTeks by major Pharmas
seeking to bolster their new drug candidates.